Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDORIL D50 vs AMTURNIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Hypertension,Edema due to congestive heart failure,Edema due to hepatic cirrhosis,Edema due to nephrotic syndrome,Edema due to corticosteroid or estrogen therapy
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
10 mg to 20 mg orally once daily, with or without food.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Amiloride is not metabolized and is excreted unchanged in the urine. Hydrochlorothiazide is not extensively metabolized; the majority is excreted unchanged in the urine via renal tubular secretion.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
~20% bound to albumin; minimal binding to other plasma proteins.
98% bound to albumin and alpha-1-acid glycoprotein.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Vd = 0.15–0.25 L/kg; indicates primarily extracellular distribution.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Oral: 40–50% due to first-pass metabolism.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR 15-29 m L/min/1.73 m²: reduce dose to 10 mg once daily. e GFR <15 m L/min/1.73 m² or dialysis: not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 10 mg once daily. Child-Pugh C: not recommended.
Not recommended; inadequate safety data.
Safety and efficacy not established; no recommended dose.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
No specific dose adjustment required, but monitor renal function closely due to age-related decline.
None
No FDA boxed warning.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hyperkalemia: Risk is increased in patients with renal impairment, diabetes, or elderly. Monitor serum potassium levels.,Hypersensitivity reactions: May occur with sulfonamide derivatives (hydrochlorothiazide).,Acute angle-closure glaucoma: Has been reported with sulfonamide derivatives.,Electrolyte imbalances: Including hyponatremia, hypochloremia, hypomagnesemia, and hypokalemia.,Renal impairment: Use with caution; may precipitate azotemia.,Hepatic impairment: Use with caution; may precipitate hepatic encephalopathy.,Diabetes: Thiazides may impair glucose tolerance.,Gout: Thiazides may increase serum uric acid levels.,SLE exacerbation: Thiazides may exacerbate systemic lupus erythematosus.
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Anuria,Acute or chronic renal insufficiency,Severe renal impairment (e GFR <30 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs,Concomitant use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium (e.g., ACE inhibitors, ARBs)
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Administration with food decreases absorption and may reduce efficacy. Take at least 30 minutes before a meal. No specific food-drug interactions reported.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at maternal toxic doses. There are no adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: unknown risk. Second/third trimester: potential for fetal renal effects due to mineralocorticoid receptor blockade.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No data on presence in human milk. Finerenone and its metabolites are excreted in rat milk. M/P ratio not determined in humans. Due to potential for serious adverse reactions in nursing infants (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
No specific dose adjustments established. Pharmacokinetics may be altered due to increased volume of distribution and renal plasma flow; however, no data exist. Use lowest effective dose if essential. Monitor for hyperkalemia and hypotension, which may require dose reduction or discontinuation.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
AMTURNIDE is a first-in-class guanylate cyclase-C receptor agonist for irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid secretion and transit without significant systemic absorption. Onset of action may occur within 24 hours, but full response may take 2-4 weeks. Avoid in patients with known or suspected mechanical gastrointestinal obstruction. Dose adjustment not required for renal or hepatic impairment.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
Take once daily on an empty stomach at least 30 minutes before the first meal of the day.,Do not crush or chew the capsule; swallow whole with water.,Common side effects include diarrhea, abdominal pain, and flatulence; diarrhea is most frequent.,Seek medical attention if you experience severe or bloody diarrhea.,Notify your doctor if you are pregnant, breastfeeding, or have a history of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDORIL D50 vs AMTURNIDE, answered by our medical review team.
ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. AMTURNIDE is a Antihypertensive Combination that works by AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDORIL D50 and AMTURNIDE depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. The standard adult dose of AMTURNIDE is: 10 mg to 20 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDORIL D50 and AMTURNIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. AMTURNIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.